Nykode Therapeutics As (VACBF) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nykode Therapeutics Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.017 Greetings, and welcome to the NICO Therapeutics Second Quarter 2025 Strategy Update and 00:00:05.017 -- 00:00:09.603 Results Webcast. At this time, all participants are in listen-only mode. 00:00:09.603 -- 00:00:12.347 A question-and-answer session will follow the formal presentation. 00:00:12.347 -- 00:00:16.713 You may ask a question at any time by typing it into the Ask a Question feature on your 00:00:16.713 -- 00:00:18.174 screen. 00:00:18.174 -- 00:00:20.257 As a reminder, this conference is being recorded. 00:00:20.257 -- 00:00:24.002 It's now my pleasure to turn the call over to CEO Michael Ensig. 00:00:24.002 -- 00:00:26.503 Please go ahead, Michael. 00:00:26.710 -- 00:00:32.476 Thank you very much, Kevin, and also from my side, a very warm welcome to everybody 00:00:32.476 -- 00:00:37.602 to this Q2 webcast, and not least, our long-anticipated strategy 00:00:37.602 -- 00:00:42.848 update from MyCode. Before moving on, I just want to remind 00:00:42.848 -- 00:00:45.090 every one of you of our forward-looking statements. 00:00:45.090 -- 00:00:50.015 We assume you are familiar with those, and on that basis, I'll quickly move on. 00:00:50.015 -- 00:00:55.522 As usual, I am very pleased to have with me here today Ander Fredriksson, our co-founder 00:00:55.522 -- 00:00:59.567 and CSO, and Al Gurvin, our CFO. 00:00:59.567 -- 00:01:04.913 Before moving into the strategy update, which I believe you've all been waiting 00:01:04.913 -- 00:01:10.180 for at this time point here, we'll just very quickly or briefly review the 00:01:10.180 -- 00:01:15.266 key highlights from our Q2 report, which was also announced or issued 00:01:15.266 -- 00:01:18.357 this morning here. And 00:01:18.357 -- 00:01:22.885 because we are focusing most of th...